Skip to main content

Table 1 Selected agents in first line for advanced HCC

From: Emerging therapies in advanced hepatocellular carcinoma

Trial Phase Mechanism of action Primary endpoint OS (months) PFS (months) ORR (%)
Sorafenib vs placebo
(SHARP)
III Multi-targeted TKI OS 10.7 vs 7.9 months
(p < 0.001)
5.5 vs 2.8 months
(p < 0.001)
2
Lenvatinib vs sorafenib
(REFLECT)
III Multi-targeted TKI OS, non-inferiority 13.6 vs 12.3 months (HR = 0.92; 95% CI 0.79–1.06) 8.9 vs 3.7 months
(p < 0.0001)
24.1 vs 9.2
(p < 0.0001)
Sunitinib vs sorafenib III Multi-targeted TKI OS 7.9 vs 10.2 months
(p = 0.0014)
3.6 vs 3.0 months
(p = 0.22)
Sorafenib + erlotinib vs sorafenib + placebo III EGFR TKI OS 9.5 vs 8.5 months
(p = 0.408)
3.2 vs 4 months
(p = 0.18)
6.6 vs 3.9
(p = 0.102)
Bevacizumab + Erlotinib II EGFR TKI
Anti-VEGF
PFS 13.7 months 7.2 months 24
Sorafenib + doxorubicin vs sorafenib alone III Multi-targeted TKI
Cytotoxic agent
OS 9.3 vs 10.5 months 3.6 vs 3.2 months
Bevacizumab II Anti-VEGF PFS 6.9 months 13
Ramicirumab II Anti-VEGF PFS 12 months 4 months 9.5
  1. TKI tyrosine kinase inhibitor, EGFR epidermal growth factor receptor, VEGFR vascular endothelial growth factor, OS overall survival, PFS progression free survival